首页> 外国专利> Sphingoglycolipids as markers for multidrug resistant cancers

Sphingoglycolipids as markers for multidrug resistant cancers

机译:鞘脂糖脂作为多药耐药性癌症的标志物

摘要

The present invention involves the identification of sphingoglycolipid species that are indicative of multidrug resistance in certain types of cells, including cancer cells. The association of multidrug resistance with the expression of certain sphingoglycolipids provides a new method for identifying multidrug resistant cancers. In addition, it has been determined that reducing the levels of certain sphingoglycolipids results in enhanced chemosensitivity of drug resistant cancer cells. This offers the opportunity to develop new treatments for multidrug resistant cancers.
机译:本发明涉及鞘脂糖脂种类的鉴定,该物质指示某些类型的细胞(包括癌细胞)中的多药耐药性。多药耐药性与某些鞘脂糖脂的表达之间的联系提供了一种鉴定多药耐药性癌症的新方法。另外,已经确定降低某些鞘脂糖脂的水平导致增强的耐药性癌细胞的化学敏感性。这提供了开发针对多药耐药性癌症的新疗法的机会。

著录项

  • 公开/公告号US6090565A

    专利类型

  • 公开/公告日2000-07-18

    原文格式PDF

  • 申请/专利权人 JOHN WAYNE CANCER INSTITUTE;

    申请/专利号US19970964656

  • 发明设计人 MYLES CABOT;

    申请日1997-11-05

  • 分类号G01N33/567;G01N33/53;G01N33/574;G01N33/48;

  • 国家 US

  • 入库时间 2022-08-22 01:36:39

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号